Humanized mouse models have shown that dual immunotherapy of PD‐1/CTLA‐4 inhibitors induces severe interstitial nephritis and vasculitis compared with monotherapy, with CD4+ T cell aggregation in the affected tissues, consistent with the renal pathological phenotype in patients [255]. Here, CTLA4 is linked to vasculitis.